Sanofi has finalized its takeover of Vigil Neuroscience for roughly $470 million, acquiring all outstanding shares at $8 each and issuing a $2-pe ...

Paris Thursday, August 7, 2025, 10:00 Hrs [IST] Sanofi announces the completion of its acquisition of Vigil Neuroscience, I ...

Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”). This acquisition ...

Sanofi finalise l’acquisition de Vigil Neuroscience, Inc. Paris, le 6 août 2025. Sanofi annonce la finalisation de l’acquisition de Vigil Neuroscience, Inc. (« Vigil »). Cette acquisition renforce le ...

Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”). This acquisition ...

Cognition Therapeutics’ therapy showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients.

Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease ...

Subtle differences in an mRNA sequence enables a ribosome to produce more or less of a certain protein. A new AI model called ...

Sanofi and Kling Bio have entered into a partnership aimed at accelerating the discovery of neutralising antibodies. The ...

In this webinar, learn how Sanofi is building an integrated wet and digital lab environment to accelerate large molecule ...

French pharmaceutical and healthcare company Sanofi has agreed to buy the British biotechnology firm Vicebio for up to $1.6bn. Read more.